Literature DB >> 1554493

Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.

G Kronborg1, G H Shand, A Fomsgaard, N Høiby.   

Abstract

Sputum samples from seven patients with cystic fibrosis and chronic P. aeruginosa lung infection were investigated for immune complexes by PEG precipitation and in two different complement binding assays. All seven patients were immune complex positive. The components involved in immune complex formation were identified by SDS-PAGE and immunoblotting. We found P. aeruginosa lipopolysaccharide as a major antigen. Both core and O-specific saccharide antigens could be demonstrated. IgG and IgA were the immunoglobulins involved, with IgG2 as the dominating IgG subclass. Lipopolysaccharide has a number of biological activities and its presence in sputum may have consequences for the pathogenesis of lung disease in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554493

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  7 in total

1.  Nitric oxide production by polymorphonuclear leucocytes in infected cystic fibrosis sputum consumes oxygen.

Authors:  M Kolpen; T Bjarnsholt; C Moser; C R Hansen; L F Rickelt; M Kühl; C Hempel; T Pressler; N Høiby; P Ø Jensen
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

2.  Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.

Authors:  T D Petersen; O Ciofu; T Pressler; B Giwercman; S S Pedersen; N Høiby
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

3.  Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.

Authors:  Allan W Cripps; Keith Peek; Margaret Dunkley; Kevin Vento; Joanne K Marjason; Madonna E McIntyre; Phil Sizer; Duncan Croft; Lis Sedlak-Weinstein
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

4.  Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis.

Authors:  G Kronborg; T Pressler; A Fomsgaard; C Koch; N Høiby
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

5.  Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.

Authors:  Joshua T Thaden; Ashley E Keller; Norah J Shire; M Margarita Camara; Linda Otterson; Mike Huband; Caitlin M Guenther; Wei Zhao; Paul Warrener; C Kendall Stover; Vance G Fowler; Antonio DiGiandomenico
Journal:  J Infect Dis       Date:  2015-09-02       Impact factor: 5.226

6.  Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.

Authors:  G Kronborg; A Fomsgaard; C Galanos; M A Freudenberg; N Høiby
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

7.  Enhancement of lipopolysaccharide-induced tumor necrosis factor secretion by hyperimmune serum from chronic infected patients.

Authors:  G Kronborg; A Fomsgaard; N Høiby
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.